Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019

Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28 LOS ANGELES (February 12, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial […]

Leave Your Comments »

Ritter Pharmaceuticals To Present at Noble Capital Markets’ Fifteenth Annual Investor/Equity Conference on January 28, 2019

LOS ANGELES (January 22, 2019) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance […]

Leave Your Comments »

Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES (December 4, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress

LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Closing of $6.0 Million At-Market Private Placement of Series B Convertible Preferred

Proceeds Expected to be Sufficient to Fund Company’s Liberatus Phase 3 Clinical Trial for RP-G28 for Lactose Intolerance Through Announcement of Top-Line Data Anticipated in the Second Half of 2019 LOS ANGELES (November 6, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the […]

Leave Your Comments »

Ritter Pharmaceuticals Announces Agreement for $6.0 Million At-Market Private Placement of Series B Convertible Preferred Stock and Warrants

LOS ANGELES, Oct. 31, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases (GI) with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Presents Additional Phase 2b Data Showing Adaptation of the Gut Microbiome in Lactose Intolerance Patients at American College of Gastroenterology Scientific Meeting

LOS ANGELES (October 9, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance […]

Leave Your Comments »

Ritter Pharmaceuticals to Present at 20th Annual HC Wainwright Global Investment Conference on September 5, 2018

LOS ANGELES, Aug 28, 2018 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for […]

Leave Your Comments »

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress

LOS ANGELES (August 14, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance, […]

Leave Your Comments »

Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance

Conference Call Today – June 27, 2018 at 4:30 p.m. ET LOS ANGELES (June 27, 2018) – Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with […]

Leave Your Comments »

Featuring Recent Posts WordPress Widget development by YD